UBS lowers CACI International stock price target on valuation
UBS lowered its price target on CACI International (NYSE:CACI) to $823 from $826, maintaining a Buy rating. The defense contractor expects strong organic growth and margin expansion. CACI reported Q1 fiscal 2027 EPS of $7.66, beating estimates, but revenue was slightly below expectations. Stifel raised its price target to $925 from $892, citing strong margin performance.
How this was made
The 30-second read
Why it matters
Analyst target adjustments reflect a split view: UBS trims valuation modestly, while Stifel lifts it, indicating uncertainty about the sustainability of margin expansion versus revenue growth.
Market read
The earnings release and subsequent analyst actions provide a fresh data point for traders, offering a limited but actionable edge in the short term.
What to watch
Backlog growth and high book‑to‑bill ratio suggest future revenue upside that may not be fully priced yet.
Background
CACI International, a U.S. defence contractor, reported FY2027 Q1 results with an EPS beat and a slight revenue shortfall, prompting analyst price‑target revisions.
Ticker impact
UBS lowered its price target to $823 and Stifel raised its target to $925 after CACI reported Q1 FY2027 earnings that beat EPS expectations but missed revenue estimates.
potential modest upside as Stifel's target raise may outweigh UBS's slight cut, but price may stay range‑bound pending further guidance.
Earnings beat on EPS and margin expansion are positive, yet revenue miss and a lower UBS target introduce caution. The net effect is limited upside pressure.
Market effects
Defence and technology services sector may see modest re‑rating as analysts adjust valuations based on margin trends.
U.S. defence contractors could experience slight price movement in line with CACI's mixed guidance.
Limited; impact confined to U.S. listed defence tech equities.
Counterpoint
Investors could short CACI if they believe the revenue miss signals deeper demand weakness despite margin gains.
Key entities
- AnalystUBS
Reduced price target to $823 from $826.
- AnalystStifel
Raised price target to $925 from $892.
